What is the story about?
What's Happening?
Pomerantz LLP is investigating claims against Valneva SE following safety concerns related to its chikungunya virus vaccine, IXCHIQ. The U.S. Centers for Disease Control and Prevention (CDC) reported hospitalizations for cardiac and neurologic events among individuals aged 65 and older after receiving the vaccine. This announcement led to a decline in Valneva's American Depositary Receipt (ADR) price by 13.57%, closing at $6.75 per ADR on February 28, 2025. Further, the U.S. Food and Drug Administration suspended the marketing application for IXCHIQ due to these safety concerns, causing another drop in ADR price by 18.99%, closing at $9.43 per ADR on August 25, 2025.
Why It's Important?
The investigation into Valneva SE is crucial as it addresses potential public health risks and financial implications for investors. Safety concerns surrounding vaccines can lead to significant regulatory actions and impact public trust in pharmaceutical companies. The suspension of the marketing application by the FDA underscores the seriousness of the issue, potentially affecting Valneva's market position and financial stability. Investors may face losses due to the declining ADR prices, and the case highlights the need for rigorous safety evaluations in the pharmaceutical industry.
What's Next?
Investors affected by the decline in Valneva's ADR prices are advised to contact Pomerantz LLP to consider joining the class action lawsuit. The investigation may lead to legal proceedings against Valneva and its officers, potentially resulting in compensation for investors. Regulatory bodies may continue to scrutinize Valneva's practices, and the company may need to address safety concerns to restore confidence in its products.
AI Generated Content
Do you find this article useful?
